SERPINA9 (Serpin Family A Member 9)

News alerts, weekly reports and conference planners

12ms

Tumor gene expression signatures associated with outcome in large B-cell lymphoma treated with CD19-directed CAR T-cell therapy (axicabtagene ciloleucel). (PubMed, Front Oncol)

The 6-GES was reduced, whereas the 17-GES was elevated at progression post axi-cel, consistent with the notion that these signatures represent features relevant for response and resistance to CAR T-cell therapy. Our transcriptomic analysis identified gene expression signatures potentially predictive of outcome with CD19-directed CAR T-cell therapy, and these findings are informative for risk stratification and development of next-generation products.

12 months ago

Journal • IO biomarker

ER (Estrogen receptor) • BCL2 (B-cell CLL/lymphoma 2) • ARID1A (AT-rich interaction domain 1A) • CD19 (CD19 Molecule) • KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • CCL2 (Chemokine (C-C motif) ligand 2) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • SLC16A1 (Solute Carrier Family 16 Member 1) • CCL22 (C-C Motif Chemokine Ligand 22) • SOX11 (SRY-Box Transcription Factor 11) • TNFSF4 (TNF Superfamily Member 4) • DUSP5 (Dual Specificity Phosphatase 5) • KLRB1 (Killer Cell Lectin Like Receptor B1) • NKG2D (killer cell lectin like receptor K1) • SERPINA9 (Serpin Family A Member 9) • SIGLEC5 (Sialic Acid Binding Ig Like Lectin 5)

Yescarta (axicabtagene ciloleucel)

over1year

Genomic analysis reveals molecular characterization of CD30+ and CD30- extranodal natural killer/T-cell lymphomas (ENKTLs). (PubMed, Hum Pathol)

Immunohistochemical analysis revealed that the expression pattern of BCL10 in normal lymphoid tissues was similar to that of BCL2; however, its expression in ENKTL cells was significantly higher (67.92% vs. 16.98%), implying the potential application of BCL10 inhibitors for treating ENKTLs. These results provide new insights into the genetic characteristics of CD30+ and CD30- ENKTLs, and could facilitate the clinical development of novel therapies for ENKTL.

over 1 year ago

Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CCND3 (Cyclin D3) • KDM5A (Lysine Demethylase 5A) • MUC6 (Mucin 6) • SERPINA9 (Serpin Family A Member 9) • USP32 (Ubiquitin Specific Peptidase 32) • USP7 (Ubiquitin Specific Peptidase 7)

almost2years

Inflammatory and subtype-dependent serum protein signatures predict survival beyond the ctDNA in aggressive B cell lymphomas. (PubMed, Med)

Altogether, we discovered distinct serum protein landscapes that dissect the heterogeneity of LBCLs and provide agile, minimally invasive tools for precision oncology.

almost 2 years ago

Journal • Circulating tumor DNA

SERPINA9 (Serpin Family A Member 9)

2years

Association between serum multi-protein biomarker profile and real-world disability in multiple sclerosis. (PubMed, Brain Commun)

Stacking classification model using five functional pathways to represent multiple proteins as meta-features implicated those involved in neuroaxonal integrity as significant contributors to predictive performance. Thus, serum multi-protein biomarker profiles improve the prediction of real-world MS disability status beyond clinical profile alone or clinical profile plus single protein biomarker, reaching clinically actionable performance.

2 years ago

Journal • Real-world evidence • Real-world

TNFA (Tumor Necrosis Factor-Alpha) • VCAN (Versican) • CDCP1 (CUB Domain Containing Protein 1) • CNTN2 (Contactin 2) • GFAP (Glial Fibrillary Acidic Protein) • NEFL (Neurofilament Light Chain) • SERPINA9 (Serpin Family A Member 9)

2years

Transcriptomic Signature and Functional Abnormalities of Bone Marrow Mesenchymal Stromal Cells Mediate Disease Progression of Myelodysplastic/Myeloproliferative Neoplasms (ASH 2023)

Pre-treatment of SD-MSC feeder with the hypomethylating agent 5-azacytidine improved the clonogenic potential of the corresponding co-cultured HSPC, but did not restore the HSPC colony yield with HR-MSC feeder...ConclusionTogether, our data point towards a degree of co-development and communication between MSC and HSPC during disease progression of MDS/MPN. Further characterization of the unique functional and transcriptomic signatures in MSC may help to optimize disease prognostication and identify novel therapeutic targets in MDS/MPN patients.

2 years ago

IO biomarker • Stroma

CD74 (CD74 Molecule) • IL6 (Interleukin 6) • CD34 (CD34 molecule) • COL1A1 (Collagen Type I Alpha 1 Chain) • PODXL (Podocalyxin) • SERPINA9 (Serpin Family A Member 9)

IL6 expression

azacitidine

over2years

Establishment and Clinical Significance of Prognostic Nomogram Model for Diffuse Large B-Cell Lymphoma Based on Immunohistochemistry Markers and International Prognostic Index Scores (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)

The nomogram model incorporating clinical characteristics and IHC biomarkers has good discrimination and calibration, which provides a useful tool for the risk stratification of DLBCL.

over 2 years ago

Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • LMO2 (LIM Domain Only 2) • SERPINA9 (Serpin Family A Member 9)

BCL2 expression • MYC expression

Rituxan (rituximab)

almost3years

Genomic and transcriptomic analyses identify distinct features of triple-negative inflammatory breast cancer (AACR 2023)

Patients were treated with neoadjuvant chemotherapy (NAC) or the anti-EGFR antibody panitumumab (PmAb) plus NAC (PmAb/NAC)... Our study demonstrated distinct genetic abnormalities, immune responses, and molecular characteristics associated with TN-IBC as well as differences related to patients’ responses to NAC and PmAb/NAC. This first comprehensive genomic, transcriptomic, and immune profiling of the largest TN-IBC patient cohort improves our understanding of the molecular landscape of the most aggressive subtype of breast cancer. Our analysis could lead to the discovery of novel prognostic biomarkers and druggable targets for TN-IBC.

almost 3 years ago

Tumor mutational burden • BRCA Biomarker

TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RB1 (RB Transcriptional Corepressor 1) • KEAP1 (Kelch Like ECH Associated Protein 1) • CD8 (cluster of differentiation 8) • PALB2 (Partner and localizer of BRCA2) • LMNA (Lamin A/C) • DDR2 (Discoidin domain receptor 2) • CDKN1B (Cyclin dependent kinase inhibitor 1B) • GATA3 (GATA binding protein 3) • NDRG1 (N-Myc Downstream Regulated 1) • BCL9 (BCL9 Transcription Coactivator) • SERPINA9 (Serpin Family A Member 9)

KEAP1 mutation • BRCA1 expression • BRCA2 expression

Vectibix (panitumumab)

over3years

Serum Proteome Profiling Reveals Inflammatory, Molecular and Prognostic Information Beyond the Ctdna in Aggressive B-Cell Lymphomas (ASH 2022)

Moreover, by integrating serum protein and plasma ctDNA profiling we uncover new associations that broaden the opportunities of liquid biopsies in LBCL. Together, our data establish a novel interaction between lymphoma and the host.

over 3 years ago

PD(L)-1 Biomarker • IO biomarker • Circulating tumor DNA

PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • SERPINA9 (Serpin Family A Member 9) • TNFRSF13B (TNF Receptor Superfamily Member 13B)

TP53 mutation • TP53 expression